CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($) $ in Thousands	Total	Public Offerings, Net of Underwriting Discounts and Commissions and Offering Cost [Member]	Lilly	Common Stock [Member]	Common Stock [Member] Public Offerings, Net of Underwriting Discounts and Commissions and Offering Cost [Member]	Common Stock [Member] Lilly	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member] Public Offerings, Net of Underwriting Discounts and Commissions and Offering Cost [Member]	Additional Paid-In Capital [Member] Lilly	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Beginning balance at Dec. 31, 2020	$ 102,263			$ 3,211			$ 490,093			$ (400,112)	$ 9,071
Beginning balance, shares at Dec. 31, 2020				31,602,953
Issuance of common stock	129,403		$ 16,477	$ 610		$ 77	128,793		$ 16,400
Issuance of common stock, shares				5,575,757		706,834
Exercise of stock options and vesting of restricted stock units	4,824			$ 42			4,782
Exercise of stock options and vesting of restricted stock units, shares				386,097
Repurchase of restricted stock units	(285)						(285)
Stock-based compensation	3,400						3,400
Currency translation adjustment	(9,391)										(9,391)
Net loss	(10,154)									(10,154)
Ending balance at Mar. 31, 2021	236,537			$ 3,940			643,183			(410,266)	(320)
Ending balance, shares at Mar. 31, 2021				38,271,641
Beginning balance at Dec. 31, 2020	102,263			$ 3,211			490,093			(400,112)	9,071
Beginning balance, shares at Dec. 31, 2020				31,602,953
Currency translation adjustment	(5,916)
Net loss	(37,542)
Ending balance at Jun. 30, 2021	219,087			$ 3,959			649,627			(437,654)	3,155
Ending balance, shares at Jun. 30, 2021				38,444,580
Beginning balance at Mar. 31, 2021	236,537			$ 3,940			643,183			(410,266)	(320)
Beginning balance, shares at Mar. 31, 2021				38,271,641
Exercise of stock options and vesting of restricted stock units	1,904			$ 19			1,885
Exercise of stock options and vesting of restricted stock units, shares				172,939
Stock-based compensation	4,559						4,559
Currency translation adjustment	3,475										3,475
Net loss	(27,388)									(27,388)
Ending balance at Jun. 30, 2021	219,087			$ 3,959			649,627			(437,654)	3,155
Ending balance, shares at Jun. 30, 2021				38,444,580
Beginning balance at Dec. 31, 2021	316,201			$ 4,481			787,869			(466,928)	(9,221)
Beginning balance, shares at Dec. 31, 2021				43,467,052
Exercise of stock options and vesting of restricted stock units	879			$ 8			871
Exercise of stock options and vesting of restricted stock units, shares				82,273
Stock-based compensation	5,334						5,334
Currency translation adjustment	(6,048)										(6,048)
Net loss	(18,893)									(18,893)
Ending balance at Mar. 31, 2022	297,473			$ 4,489			794,074			(485,821)	(15,269)
Ending balance, shares at Mar. 31, 2022				43,549,325
Beginning balance at Dec. 31, 2021	316,201			$ 4,481			787,869			(466,928)	(9,221)
Beginning balance, shares at Dec. 31, 2021				43,467,052
Currency translation adjustment	(25,969)
Net loss	(24,607)
Ending balance at Jun. 30, 2022	326,609			$ 4,711			848,623			(491,535)	(35,190)
Ending balance, shares at Jun. 30, 2022				45,866,820
Beginning balance at Mar. 31, 2022	297,473			$ 4,489			794,074			(485,821)	(15,269)
Beginning balance, shares at Mar. 31, 2022				43,549,325
Issuance of common stock		$ 47,925			$ 220			$ 47,705
Issuance of common stock, shares					2,298,906
Exercise of stock options and vesting of restricted stock units	184			$ 2			182
Exercise of stock options and vesting of restricted stock units, shares				18,589
Stock-based compensation	6,662						6,662
Currency translation adjustment	(19,921)										(19,921)
Net loss	(5,714)									(5,714)
Ending balance at Jun. 30, 2022	$ 326,609			$ 4,711			$ 848,623			$ (491,535)	$ (35,190)
Ending balance, shares at Jun. 30, 2022				45,866,820